Ertapenem
Ertapenem is a carbapenem antibiotic marketed by Merck as Invanz.[1]
![]() | |
Clinical data | |
---|---|
Trade names | Invanz |
AHFS/Drugs.com | Monograph |
License data | |
Pregnancy category | |
Routes of administration | Intramuscular, intravenous |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 90% (intramuscular) |
Protein binding | Inversely proportional to concentration; 85 to 95% |
Metabolism | Minor hydrolysis of beta-lactam ring, CYP not involved |
Elimination half-life | 4 hours |
Excretion | Renal (80%) and fecal (10%) |
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C22H25N3O7S |
Molar mass | 475.516 g/mol g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
| |
![]() ![]() |
References
- Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA (November 2011). "Carbapenems: past, present, and future". Antimicrob. Agents Chemother. 55 (11): 4943–60. doi:10.1128/AAC.00296-11. PMC 3195018. PMID 21859938.
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.